Denifanstat is Sagimet's once-daily oral pill for moderate-to-severe acne that could offer a non-antibiotic, non-retinoid option. It targets oil production directly if U.S.
testing confirms earlier results. Denifanstat blocks fatty-acid synthase (FASN), an enzyme that drives new fat creation in sebaceous glands. Less new fat means less sebum and less inflammatory signaling.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does this pill work differently?
- How well did it work at 12 weeks?
- Did benefit last for a full year?
- Who could it help most?
- When could you get it?
How does this pill work differently?
Denifanstat lowers de novo lipogenesis, the process where skin makes fresh fatty acids. That cuts sebum supply at its source. It also reduces inflammatory signaling including Th17 activation.
That approach differs from antibiotics, which target bacteria and inflammation, and from isotretinoin, which shrinks oil glands systemically. For patients, the distinction matters because long antibiotic courses raise resistance concerns. A targeted metabolic route could treat oiliness without those tradeoffs.
How well did it work at 12 weeks?
In the Ascletis-run China Phase 3 ASC40-303 with 480 patients, denifanstat 50 mg daily met all primary and secondary endpoints at 12 weeks. Managed Healthcare Executive reported 33.2% of patients reached clear or almost-clear on the Investigator's Global Assessment, versus 14.6% with placebo, in its report on deeper 52-week results.
Total lesions fell 57.4% versus 35.4% with placebo, while inflammatory lesions fell 63.5% versus 43.2%. Clear means no active breakouts on the rating scale. Almost-clear means only minimal residual redness or one or two tiny bumps remain.
Did benefit last for a full year?
In open-label extension ASC40-304, responses deepened through 52 weeks to 57% IGA success. Total lesions dropped 72% and inflammatory lesions dropped 77%, according to BioPharmSignal and Clinical Trial Vanguard citing Sagimet and Ascletis in their summary of the 52-week acne data.
Only dry eye at 5.5% and dry skin at 5.2% reached 5% incidence during long-term treatment. Those rates are low for a daily oral acne therapy. The treatment was described as generally well-tolerated across the year.
Who could it help most?
Sagimet's chief executive told Managed Healthcare Executive that a daily non-antibiotic, non-retinoid pill could spare long-term antibiotic use and isotretinoin burdens. That profile fits adults and teens who relapse after antibiotics.
It also fits patients who cannot tolerate retinoid dryness or monitoring demands. The U.S. AURORA trial is designed for this group:.
- age 12 and older with moderate-to-severe acne
- once-daily 50 mg denifanstat versus placebo for 12 weeks
- 40-week safety extension for longer follow-up
When could you get it?
According to Sagimet Biosciences via GlobeNewswire, the first patient received dosing in October 2026 in the AURORA trial announcement. AURORA plans to enroll about 800 U.S. patients, with topline results expected in the second half of 2027.
The FDA cleared the acne investigational new drug application with a Study May Proceed letter on August 13, 2026. Denifanstat remains investigational with no U.S. acne approval yet, so patients need a current prescription plan until AURORA data and regulatory review finish.